4DMedical Secures One-Year Deal With GlaxoSmithKline

MT Newswires Live
04/20

4DMedical (ASX:4DX) secured a one-year contract with GlaxoSmithKline, in collaboration with imaging data platform Flywheel Exchange, to provide its quantitative lung imaging analytics from May to support pulmonary drug development and clinical research, according to a Monday filing with the Australian bourse.

Additionally, the company's CT:VQ imaging technology obtained UK Conformity Assessed certification, allowing for the commercial deployment across both public and private healthcare providers within the UK, the filing said.

The company will also be included in the S&P/ASX 200 Index, effective before the open of trading on Monday, per the filing.

4DMedical's shares rose around 1% in morning trade Monday.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10